Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis

Nephrology

Volumn 18, Issue 3, 2013, Pages 188-193

  Maker, Garth L ^a   Siva, Brian ^b   Batty, Kevin T ^c,d   Trengove, Robert D ^a   Ferrari, Paolo ^b   Olynyk, John K ^a,d,e,f  

^a MURDOCH UNIVERSITY   (Australia)

^b Fremantle Hospital and Health Service   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e FREMANTLE HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

chelation; chronic kidney disease; deferasirox; ferritin; iron overload

Indexed keywords

DEFERASIROX; ERYTHROPOIETIN; IRON;

AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; STEADY STATE; TREATMENT DURATION;

AGED; ANEMIA, IRON-DEFICIENCY; AREA UNDER CURVE; BENZOATES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HEMATINICS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TANDEM MASS SPECTROMETRY; TRIAZOLES; WESTERN AUSTRALIA;

EID: 84874499744     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12035     Document Type: Article

References (27)

1. Chua AC, Graham RM, Trinder D, Olynyk JK,. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 2007; 44: 413-459.
2. Andrews NC,. Disorders of iron metabolism. N. Engl. J. Med. 1999; 341: 1986-1995.
3. Milman N,. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin. Nephrol. 1982; 17: 77-81.
4. Ferrari P, Xiao J, Ukich A, Irish A,. Estimation of glomerular filtration rate: Does haemoglobin discriminate between ageing and true CKD? Nephrol. Dial. Transplant. 2009; 24: 1828-1833.
5. Zaritsky J, Young B, Wang HJ, et al. Hepcidin: A potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4: 1051-1056.
6. Carter RA, Hawkins JB, Robinson BH,. Iron metabolism in the anaemia of chronic renal failure. Effects of dialysis and of parenteral iron. Br. Med. J. 1969; 3: 206-210.
7. Valderrabano F,. Erythropoietin in chronic renal failure. Kidney Int. 1996; 50: 1373-1391.
8. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am. J. Kidney Dis. 2006; 47 (5 Suppl. 3): S11-145.
9. Unger EF, Thompson AM, Blank MJ, Temple R,. Erythropoiesis-stimulating agents: Time for a reevaluation. N. Engl. J. Med. 2010; 362: 189-192.
10. Macdougall I, Tucker B, Thompson J, Tomson C, Baker L, Raine A,. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50: 1694-1699.
11. Taylor J, Peat N, Porter C, Morgan A,. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol. Dial. Transplant. 1996; 11: 1079-1083.
12. Ferrari P, Kulkarni H, Dheda S, et al. Serum markers are inadequate for guiding iron repletion in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2011; 6: 77-83.
13. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR,. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008; 48: 991-1001.
14. Addis A, Loebstein R, Koren G, Einarson T,. Meta-Analytic review of the clinical effectiveness of oral deferiprone (L1). Eur. J. Clin. Pharmacol. 1999; 55: 1-6.
15. Steinhauser S, Heinz U, Bartholoma M, Weyhermuller T, Nick H, Hegetschweiler K,. Complex formation of ICL670 and related ligands with FeIII and FeII. Eur. J. Inorg. Chem. 2004; 2004: 4177-4192.
16. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.
17. Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in β-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab. Dispos. 2010; 38: 808-816.
18. Rouan M, Marfil F, Mangoni P, Sechaud R, Humbert H, Maurer G,. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J. Chromatogr. B. Biomed Sci. Appl. 2001; 755: 203-213.
19. Chauzit E, Bouchet S, Micheau M, et al. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application. Ther. Drug Monit. 2010; 32: 476-481.
20. Olynyk JK, Gan E, Tan T,. Predicting iron overload in hyperferritinemia. Clin. Gastroenterol. Hepatol. 2009; 7: 359-362.
21. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-Associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study. Am. J. Med. 2012; 125: 991-999.
22. Kruger P, Leahy M, Olynyk J,. Assessing iron overload: Are we there yet? Clin. Cancer Res. 2012; 18: 6395-6397.
23. Wermke M, Schmidt A, Middeke J, et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin. Cancer Res. 2012; 18: 6460-6468.
24. Galanello R, Piga A, Alberti D, Rouan M-C, Bigler H, Sechaud R,. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J. Clin. Pharmacol. 2003; 43: 565-572.
25. Weiss H, Fresneau M, Camenisch G, Kretz O, Gross G,. In vitro blood distribution and plasma protein binding of the iron chelator deferasirox (ICL670) and its iron complex Fe-[ICL670]2 for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab. Dispos. 2006; 34: 971-975.
26. Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J. Pharmacol. Exp. Ther. 2007; 320: 978-985.
27. Pere P, Salonen M, Jokinen M, Rosenberg P, Neuvonen P, Haasio J,. Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block. Anesth. Analg. 2003; 96: 563-569.